Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Fig. 5

Estimates of Post-progression Survival and the Annual hazard rate for death after progression. A 48 of 81 (59.3%) patients in the P + C group and 60 of 63 (95.2%) patients in the CA group died. B Annual hazard rate for death after PD. C 15 of 35 (42.9%) patients who continued with PD-1/PD-L1 inhibitors after PD and 33 of 46 (71.7%) patients who discontinued PD-1/PD-L1 inhibitors died. D Annual hazard rate for death after PD in the P + C group. Abbreviations: PD-1/L1, anti-PD-1or anti-PD-L1 agents; PD, progressive disease; HR, hazard ratio

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us